Medical organizations claim that the US Food and Drug Administration is restricting access to the abortion pill Mifeprex (mifepristone) by requiring patients to pick it up in-person at a clinic or medical office as required under the product's Risk Evaluation and Mitigation Strategy. They say the FDA has waived REMS enforcement for other drugs requiring in-person visits during the COVID-19 pandemic and the same policy should apply to mifepristone.
The American Civil Liberties Union filed suit against FDA on 27 May in the US District Court for the...
